BloodStream

On the latest episode of BloodStream, Patrick sits down with Cassie Miller, a parent raising two daughters with von Willebrand disease. Together, they talk about staying solution-focused, trusting your instincts, and advocating when the path forward isn't clear.

Jeff and Barb return to the podcast with therapist Gary McClain for a thoughtful conversation about the emotional side of living with a rare disease, exploring resilience, difficult emotions, and how we support ourselves and one another.

Show Notes:

LevelsMatter.com

Presenting Sponsor:

Takeda, visit bleedingdisorders.com to learn more.

I'm Fine is presented by @SanofiUS

Subscribe:

The BloodStream Podcast

Connect with BloodStream Media:

BloodStreamMedia.com

BloodStream on Facebook

BloodStream on X/Twitter

BloodStream on Instagram

BloodStream on LinkedIn

BloodStream on TikTok

Please see https://www.pfi.sr/HYMPAVZI_PI for Full PI.

#HYMPAVZISponsored William S. Somers, Ph.D., was a biotherapeutics research and development leader with more than 30 years of experience across biotechnology and pharmaceutical organizations, including Pfizer.

As a scientist living with hemophilia, Dr. Somers played a key role in driving the patient-centric and purposeful design of HYMPAVZI (marstacimab-hncq). This episode will explore how the patient perspective influenced the scientific journey, with a special focus on Will's research and why it was personally important for him to bring HYMPAVZI to people with hemophilia.

HYMPAVZI may cause serious side effects, including blood clots (thromboembolic events). HYMPAVZI may increase the risk for your blood to clot in blood vessels in your arm, leg, lung, or head, which can be life-threatening. To learn more about this risk and additional safety information visit HYMPAVZI.com.

This post is directed to a U.S. audience and may not be suitable outside of the U.S. This video is intended to be viewed as it was originally produced in partnership with Pfizer. Remember, this content is for educational purposes only and does not replace discussions with a healthcare provider.

PP-HYM-USA-1267

Show Notes:

For safety information visit: https://labeling.pfizer.com/ShowLabeling.aspx?id=20916&Section=PPI

For information on how to navigate your treatment journey, visit the Shared Decision-making Guide here.

Listen and subscribe where you get your podcasts! #Hemophilia

IMPORTANT SAFETY INFORMATION

Important: Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX products or "bypassing agents" (products that help blood clot but work in a different way than HYMPAVZI).

Your healthcare provider may prescribe factor VIII or factor IX medicines or bypassing agents to treat episodes of breakthrough bleeding during your treatment with HYMPAVZI. Carefully follow your healthcare provider's instructions regarding when to use these medicines and the prescribed dose during your treatment with HYMPAVZI. Do not use additional doses of HYMPAVZI to treat breakthrough bleeds.

Before using HYMPAVZI, tell your healthcare provider about all of your medical conditions, including if you:

• have a planned surgery. Your healthcare provider may stop treatment with HYMPAVZI before your surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery.

• have a severe short-term (acute) illness such as an infection or injury.

• have been told that you have a risk for blood clots.

• are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn baby.

Females who are able to become pregnant:

• Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI.

• Use effective birth control (contraception) during treatment with HYMPAVZI and for at least 2 months after the last dose of HYMPAVZI.

• Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI.

• are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

If you inject too much HYMPAVZI, call your healthcare provider or the Poison Help Line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

What are the possible side effects of HYMPAVZI? HYMPAVZI may cause serious side effects, including:

• blood clots (thromboembolic events). HYMPAVZI may increase the risk for your blood to clot in blood vessels in your arm, leg, lung, or head, which can be life-threatening. Blood clots have happened in people using HYMPAVZI. You may have an increased risk of blood clots if you have certain risk factors. Stop using HYMPAVZI and get medical help right away if you develop any of these signs or symptoms of blood clots:

• swelling or pain in your arms or legs

• redness or discoloration in your arms or legs

• shortness of breath

• pain in chest or upper back

• fast heart rate

• cough up blood

• feeling faint

• headache

• numbness in your face

• eye pain or swelling

• trouble seeing

• allergic reactions. HYMPAVZI may cause allergic reactions, including rash and itching. Stop using HYMPAVZI and get medical help right away if you develop any of the following symptoms of a severe allergic reaction:

• swelling of your face, lips, mouth, or tongue

• trouble breathing

• wheezing

• dizziness or fainting

• fast heartbeat or pounding in your chest

• sweating

The most common side effects of HYMPAVZI include:

• swelling, hardening, redness, bruising, bleeding, and pain at injection site

• headache

• fever

• joint pain

• diarrhea

• itching

• rash

These are not all the possible side effects of HYMPAVZI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

What is HYMPAVZI?

HYMPAVZI is a prescription medicine used regularly to prevent or reduce the frequency of bleeding episodes in adults and children 6 years of age and older with:

• hemophilia A with or without factor VIII inhibitors, or

• hemophilia B with or without factor IX inhibitors.

It is not known if HYMPAVZI is safe and effective in people receiving ongoing Immune Tolerance Induction (ITI).

It is not known if HYMPAVZI is safe and effective in children younger than 6 years of age.

On the latest episode of BloodStream, Patrick and Amy introduce The Flow podcast rebrand, preview our upcoming Hemophilia B series with Zebra for Care, and share the latest hot tips for sending your kids to camp.

Listen now and subscribe to BloodStream wherever you get your podcasts so you do not miss what is coming next.

Show Notes:

Project Elevate Her

Presenting Sponsor:

Takeda, visit bleedingdisorders.com to learn more.

Subscribe:

The BloodStream Podcast

Connect with BloodStream Media:

BloodStreamMedia.com

BloodStream on Facebook

BloodStream on X/Twitter

BloodStream on Instagram

BloodStream on LinkedIn

BloodStream on TikTok

The FED UP Act is headed to Congress and could reshape how women and girls with bleeding disorders are diagnosed, treated, and supported!

On the latest episode of BloodStream, Amy and Patrick sit down with Joe Stanco, HTC Family Nurse Practitioner and founder of the Hemostasis and Thrombosis Nursing Association, for a candid conversation about today's hemophilia care landscape and where it is headed next. We also unpack what this bipartisan legislation could mean for access, research, education, and equity in care.

In this week's I'm Fine segment, we explore the emotional weight of caregiving, the pressure to always show up for others, and what happens when your own care starts to fall to the bottom of the list.

Advocacy, science, and lived experience all in one place. Listen now and subscribe to BloodStream Podcast wherever you get your shows.

Show Notes:

FED UP Act

Presenting Sponsor:

Takeda, visit bleedingdisorders.com to learn more.

I'm Fine is presented by @SanofiUS

#bloodstreammedia #raredisease #bleedingdisorders #podcast #chronicdisease #hemophiliacommunity #advocacy

Subscribe:

The BloodStream Podcast

Connect with BloodStream Media:

BloodStreamMedia.com

BloodStream on Facebook

BloodStream on X/Twitter

BloodStream on Instagram

BloodStream on LinkedIn

BloodStream on TikTok

What does it look like to raise awareness from the top of the world?

On the latest episode of BloodStream, Maia Meier joins our beloved hosts, Patrick and Amy, to talk about her mission to climb the Seven Summits through Project Elevate Her and bring visibility to women and girls living with bleeding disorders.

From high-altitude expeditions to the everyday realities of advocacy, the conversation explores what it means to take up space in places where women with bleeding disorders have too often gone unseen.

Listen now and subscribe to BloodStream Podcast wherever you get your shows.

Show Notes:

Project Elevate Her

Presenting Sponsor:

Takeda, visit bleedingdisorders.com to learn more.

Subscribe:

The BloodStream Podcast

Connect with BloodStream Media:

BloodStreamMedia.com

BloodStream on Facebook

BloodStream on X/Twitter

BloodStream on Instagram

BloodStream on LinkedIn

BloodStream on TikTok

Please see https://www.pfi.sr/HYMPAVZI_PI for Full PI​

#HYMPAVZISponsored William S. Somers, Ph.D. is a biotherapeutics research and development leader with more than 30 years of experience across biotechnology and pharmaceutical organizations, including Pfizer.​

As a scientist living with hemophilia, Dr. Somers played a key role in driving the patient-centric and purposeful design of HYMPAVZI (marstacimab-hncq). This episode will explore how the patient perspective influenced the scientific journey, with a special focus on Will's research and why it was personally important for him to bring HYMPAVZI to people with hemophilia. To learn more and for safety information, visit HYMPAVZI.com.​

This post is directed to a U.S. audience and may not be suitable outside of the U.S. This video is intended to be viewed as it was originally produced in partnership with Pfizer. Remember, this content is for educational purposes only and is not intended to replace discussions with a healthcare provider.​

PP-HYM-USA-1071​

Show Notes:​

For prescribing information visit pfi.sr/HYMPAVZI_PI​

For information on how to navigate your treatment journey visit the shared decision-making guide here.

Listen and subscribe where you get your podcasts!​

#Hemophilia

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use HYMPAVZI safely and effectively. See full prescribing information for HYMPAVZI. HYMPAVZI (marstacimab-hncq) injection, for subcutaneous use Initial U.S. Approval: 2024

INDICATIONS AND USAGE

HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:

hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or

hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.

DOSAGE AND ADMINISTRATION

See Full Prescribing Information for important dosing and administration instructions.

The recommended dosage of HYMPAVZI is:

Loading dose: 300 mg (two 150 mg injections) by subcutaneous injection

Maintenance dose: One week after the loading dose, initiate maintenance dosing of 150 mg every week by subcutaneous injection on the same day each week, at any time of day.

Dose adjustment to 300 mg subcutaneous injection weekly can be considered.

Factor VIII and factor IX products can be administered for the treatment of breakthrough bleeds in patients receiving HYMPAVZI. Do not use additional doses of HYMPAVZI to treat breakthrough bleeds.

Temporarily discontinue HYMPAVZI before major surgery.

DOSAGE FORMS AND STRENGTHS

Injection: 150 mg/mL in a single-dose prefilled syringe

Injection: 150 mg/mL in a single-dose prefilled pen

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Thromboembolic Events: Thromboembolic events may occur. Interrupt HYMPAVZI prophylaxis if symptoms occur.

Hypersensitivity: Hypersensitivity reactions may occur. In the event of a severe allergic reaction, discontinue HYMPAVZI.

Embryofetal Toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.

ADVERSE REACTIONS

Adverse reactions reported in ≥3% of HYMPAVZI-treated patients were injection site reaction, headache, and pruritus.

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 12/2025

On the latest episode of BloodStream, we look at what is really underneath the words "I'm fine" and who it is serving to keep things that way.

In I'm Fine, a family story across generations with bleeding disorders traces what has changed, what has not, and how honesty can begin to break cycles of silence that have long been passed down. What emerges is a closer look at resilience, inheritance, and the stories we are taught to minimize.

We close out our plasma donation mini-series with donor Carver, highlighting the people behind every donation and the quiet consistency that keeps treatment possible.

Plasma, perspective, and the moments where silence finally gives way to something more honest. Listen now and subscribe to BloodStream Podcast wherever you get your shows.

Show Notes:

Presenting Sponsor:

Takeda, visit bleedingdisorders.com to learn more.

I'm Fine is presented by @SanofiUS

Subscribe:

The BloodStream Podcast

Connect with BloodStream Media:

BloodStreamMedia.com

BloodStream on Facebook

BloodStream on X/Twitter

BloodStream on Instagram

BloodStream on LinkedIn

BloodStream on TikTok

On this episode of BloodStream—our plasma donation series continues with a powerful second installment featuring donor Hannah and the story behind what it really means to give.

We've also got a packed lineup: a look at momentum building at the WFH World Congress, policy progress led by State Senator Joseph Addabbo supporting families with rare disorders, and new momentum in storytelling as Sanofi backs additional documentaries spotlighting rare blood conditions.

Plus, we dig into the bigger picture—how bleeding disorders impact entire families, the role creativity plays when navigating physical limitations, and the isolation that can come with not knowing someone who shares your experience.

And don't miss a spotlight on The Red Ink Project and their virtual screening of Dismissed, a film bringing long-overdue visibility to women and girls with bleeding disorders.

All that and more—this is BloodStream.

Show Notes:

NY State Senator Joseph Addabbo steps up for bleeding disorders

Sanofi backs 2 more documentary films about rare blood disorders

theredinkproject.org

Presenting Sponsor:

Takeda, visit bleedingdisorders.com to learn more.

Subscribe:

The BloodStream Podcast

Connect with BloodStream Media:

BloodStreamMedia.com

BloodStream on Facebook

BloodStream on X/Twitter

BloodStream on Instagram

BloodStream on LinkedIn

BloodStream on TikTok

CSL Behring just announced a global "stockout" of Hemgenix—what's happening, and what does it mean for patients? On this episode of BloodStream Podcast, we break down the news, launch our mini-series on plasma donation, and hear from Thomas Savage in our I'm Fine segment, sharing the highs, the lows, and the reality of living with a severe bleeding disorder.

Pain, perseverance, and the lessons learned along the way give a rare, unfiltered glimpse into life behind the headlines—reminding us all that every treatment, every donation, and every day matters.

Show Notes:

I'm Fine is presented by @SanofiUS

#bloodstreammedia #raredisease #bleedingdisorders #podcast #chronicdisease #hemophiliacommunity #advocacy

Presenting Sponsor:

Takeda, visit bleedingdisorders.com to learn more.

Subscribe:

The BloodStream Podcast

Connect with BloodStream Media:

BloodStreamMedia.com

BloodStream on Facebook

BloodStream on X/Twitter

BloodStream on Instagram

BloodStream on LinkedIn

BloodStream on TikTok

In this special partnered episode of the BloodStream Podcast, hosts Patrick James Lynch and Amy Board speak with hematologist Dr. Tami Singleton about hemophilia A and B with inhibitors, a complex condition that changes how bleeding episodes are treated. Dr. Singleton explains what inhibitors are, why they develop, and how they impact clotting and everyday life for patients and families. The conversation also explores SEVENFACT, a recombinant factor VIIa bypassing agent, including how it works and what patients should know about dosing and treatment planning.

Click here to learn more about SEVENFACT.